PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-51.09%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-44.77%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-95.27%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-95.63%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-93.52%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-93.52%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-93.52%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
175.02%
10Y revenue/share CAGR above 1.5x 4997.T's 77.99%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
21.78%
5Y revenue/share CAGR under 50% of 4997.T's 66.94%. Michael Burry would suspect a significant competitive gap or product weakness.
21.42%
3Y revenue/share CAGR under 50% of 4997.T's 58.45%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
131.42%
Net income/share CAGR above 1.5x 4997.T's 5.06% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
128.41%
Below 50% of 4997.T's 849.70%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
194.76%
3Y net income/share CAGR above 1.5x 4997.T's 37.92%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
138.64%
10Y equity/share CAGR above 1.5x 4997.T's 57.59%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
51.28%
5Y equity/share CAGR above 1.5x 4997.T's 32.70%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
31.75%
3Y equity/share CAGR similar to 4997.T's 31.07%. Walter Schloss sees both having parallel profitability or reinvestment over 3 years.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.18%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
23.38%
Inventory growth well above 4997.T's 9.82%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
4.02%
Asset growth above 1.5x 4997.T's 2.19%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
3.97%
Similar to 4997.T's 3.82%. Walter Schloss finds parallel capital usage or profit distribution strategies.
17.57%
Debt growth far above 4997.T's 6.93%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-100.00%
Our R&D shrinks while 4997.T invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-16.18%
We cut SG&A while 4997.T invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.